Paras Healthcare is preparing to enter the primary market with its public issue scheduled to open on 21 October 2026 and close on 23 October 2026. According to the red herring prospectus, the company operates a growing network of hospitals focusing primarily on Tier-2 cities across India. With improving bed occupancy rates and expanding operational capacity, the offering brings attention to hospital economics, cash flow management, and expansion-driven capital needs in the healthcare sector.
Paras Healthcare IPO Offering Structure and Key Parameters
The public offering comprises a fresh issue of shares alongside an offer for sale by existing promoters and investors. The price band has been established at INR 660 to INR 693 per equity share, with a minimum lot size of 21 shares. At the upper end of the price band, a single lot requires an investment of INR 14,553. A significant portion of the total issue size constitutes an offer for sale, meaning that a substantial share of the proceeds flows directly to selling shareholders rather than the company balance sheet.
| IPO Parameter | Value | Analysis |
|---|---|---|
| Issue Dates | 21 – 23 October 2026 | A standard three-day bidding window for mainboard equities. |
| Price Band | INR 660 – 693 per share | Sets the valuation benchmark at the upper limit of INR 693. |
| Fresh Issue | INR 500 crore | Direct capital infusion earmarked for corporate debt reduction and growth. |
| Offer for Sale | INR 950 crore | Represents 65.52% of the total issue, providing exit liquidity to early backers. |
| Allocation Quota | QIB 75%, NII 15%, Retail 10% | Institutional investors hold the dominant share of allocation under book-building rules. |
The primary capital raised via the fresh issue component, amounting to INR 500 crore, is designated for specific corporate objectives. A total of INR 320.90 crore will be deployed toward repaying company borrowings, while INR 54.10 crore is allocated to subsidiary PMHPL for debt clearance. The remaining balance is intended for general corporate purposes, capped at 25% of gross proceeds.
Hospital Network, Occupancy Growth and Revenue Drivers
Paras Health currently manages a network of eight hospitals with a total capacity of 2,211 beds, out of which 1,502 beds are fully operational. Core medical specialties—specifically cardiac, oncology, neuro, gastro, orthopaedics, and renal care—generate 74.70% of the company’s total revenue. The geographic footprint is heavily skewed toward Tier-2 locations, which accounted for 68.18% of revenue in fiscal year 2026.
| Operational Metric | FY24 | FY25 | FY26 | Q1 FY27 |
|---|---|---|---|---|
| Occupied Bed Days | 2,54,716 | 2,68,927 | 3,38,321 | 95,272 |
| Average Revenue Per Occupied Bed (ARPOB) | INR 44,305.65 | INR 48,088.57 | INR 47,397.82 | INR 49,351.70 |
| Occupancy Rate (%) | 52.46% | 50.78% | 61.75% | 69.72% |
The expansion in hospital performance is primarily volume-driven. During fiscal 2026, occupied bed days climbed by 25.81%, whereas average revenue per occupied bed experienced a minor contraction of 1.44%. This trend continued into the first quarter of fiscal 2027, where bed days rose by 25.89% alongside a 1.41% increase in ARPOB. However, realisations vary significantly by location. Flagship facilities such as Gurugram achieve an ARPOB of INR 74,911.63 per day, whereas newer regional units report lower figures, influenced in part by a shifting payor mix where government schemes and public sector undertakings grew from 29.76% in fiscal 2024 to 43.63% in the first quarter of fiscal 2027.
Financial Performance and Operating Margins
Financial disclosures indicate notable revenue expansion, supported by operating leverage as recently opened hospitals scale up their occupancy levels. Fiscal 2026 revenue increased by 24.10%, driven almost entirely by higher patient volumes. Concurrently, earnings before interest, tax, depreciation, and amortisation margins registered a sharp upward movement.
| Financial Metric / Cost Line | FY25 | FY26 | Change / Trend |
|---|---|---|---|
| Material Costs (% of revenue) | 26.03% | 26.79% | Marginal increase of +0.76 pts |
| Employee Costs (% of revenue) | 13.43% | 11.31% | Reduction of (2.12) pts |
| Doctor Retainers & Consultants (% of revenue) | 27.74% | 24.54% | Reduction of (3.20) pts |
| Other Expenses (% of revenue) | 22.27% | 17.89% | Reduction of (4.38) pts |
The operating margin expansion benefited from lower relative overhead and consultant costs, alongside internal cost reclassifications such as bringing radiology services in-house. Incremental revenue performance was strong, with fiscal 2026 revenue rising by INR 311.89 crore and EBITDA improving by INR 179.12 crore, resulting in an incremental margin of 57.43%.
Market Analysis and Business Evaluation
Valuation Assessment and Peer Comparison
When evaluated against listed hospital peers, Paras Healthcare commands a comparatively high price-to-earnings multiple. Based on fiscal 2026 earnings, the stock trades at a P/E of 171.09x, positioned higher than sector comparables such as Krishna Institute of Medical Sciences at 116.41x, Aster DM Quality Care at 91.89x, and Jupiter Lifeline Hospitals at 42.92x. This elevated multiple stems from a relatively small and recently recovered earnings base following a loss-making period in fiscal 2025. On return metrics, the company reported a return on net worth of 12.98%, aligning closely with industry averages.
| Peer Company | FY26 Revenue (INR crore) | P/E Ratio | Return on Net Worth (RoNW) |
|---|---|---|---|
| Paras Healthcare | 1,605.95 | 171.09x | 12.98% |
| Aster DM Quality Care | 4,643.22 | 91.89x | 9.70% |
| Jupiter Lifeline Hospitals | 1,499.79 | 42.92x | 13.41% |
| Krishna Institute of Medical Sciences | 3,904.60 | 116.41x | 11.01% |
Capital Intensity and Cash Flow Dynamics
A critical analytical consideration involves capital expenditure versus operational cash generation. Between fiscal 2024 and fiscal 2026, operating activities generated INR 342.18 crore, while total capital expenditure reached INR 503.64 crore. This funding shortfall was met primarily through external borrowings. Even after allocating INR 375 crore from the IPO proceeds toward debt retirement, the company retains adjusted borrowings of INR 513.89 crore, leading to a post-issue adjusted debt-to-equity ratio of 1.15x. Furthermore, expanding government scheme patient volumes has extended net receivables to approximately 86.60 days of revenue by June 2026, which continues to absorb operating cash flows.
Key Takeaways
- Paras Healthcare’s public issue opens on 21 October 2026 and closes on 23 October 2026 with a price band of INR 660 to INR 693 per share.
- Operational bed capacity stands at 1,502 out of a total 2,211-bed network, with overall occupancy improving to 69.72% in Q1 FY27.
- Fiscal 2026 revenue grew by 24.10%, accompanied by an expansion in EBITDA margin driven by operating leverage and reduced relative overheads.
- The valuation multiple stands at 171.09x P/E based on fiscal 2026 earnings, reflecting a compressed historical profit base.
- Proceeds from the fresh issue will primarily address debt reduction of over INR 375 crore across the entity and its subsidiaries.
- Ongoing expansion plans, including upcoming facilities like Gurugram II, will require continued monitoring of lease commitments and capital expenditure requirements.
Frequently Asked Questions
The IPO opens on 21 October 2026 and closes on 23 October 2026.
The price band is set at INR 660 to INR 693 per equity share.
The lot size is 21 shares, requiring a minimum investment of INR 14,553 at the upper end of the price band.
The fresh issue aims to raise INR 500 crore, while the offer for sale amounts to INR 950 crore.
The proceeds will be used to repay company borrowings of INR 320.90 crore, repay subsidiary PMHPL debt of INR 54.10 crore, and for general corporate purposes.
In FY26, the company reported revenue of INR 1,605.95 crore, representing a 24.10% growth over the previous period.
Paras Health operates eight hospitals with a total capacity of 2,211 beds, of which 1,502 beds are operational.
The allocation structure assigns 75% to Qualified Institutional Buyers, 15% to Non-Institutional Investors, and 10% to Retail Individual Investors.
